Sertoli Technologies Inc.
Sertoli Technologies, Inc. (STI) was founded to develop the use of Sertoli cells as localized immunoprotective therapy. The company’s lead program was a product that co-transplanted Sertoli cells with islets for the treatment of diabetes. This approach was based on work at the University of Tennessee Medical Center that showed Sertoli cells protect foreign islets from rejection by producing immune inhibitors directly at the graft site.
STI licensed exclusively to Pheremone Sciences Corp., now Sernova Corp., the rights to develop Sertoli cell based products. Sernova has initiated clinical trials with its cell therapy based products.